[ad_1]
Health officials now recommend that Americans receive booster shots of Pfizer, Moderna, and Johnson & Johnson coronavirus vaccines.
An advisory panel from the US Food and Drug Administration (FDA) has approved a booster injection of Johnson & Johnson’s COVID-19 vaccine because there are concerns that the effect of a single-dose injection of Johnson & Johnson is not as effective as previously thought.
An influential 19-person advisory panel of the US Food and Drug Administration voted unanimously on Friday to recommend that approximately 15 million people in the United States be vaccinated with the first dose of Johnson & Johnson vaccine for a second injection.
A day ago, the expert group Recommended third dose Two doses of Moderna’s vaccine, and it has previously approved Pfizer BioNTech jab.
Data collected by the Centers for Disease Control and Prevention (CDC) show that nearly 10 million people in the United States have received Pfizer booster injections, of which 188 million people (approximately 57% of the total population) have been vaccinated.
The COVID-19 vaccine and booster shots are free and widely available to U.S. citizens who need them.
The FDA will formally decide whether to authorize Johnson & Johnson and Moderna’s boosters based on the recommendations of its consultants.
Johnson & Johnson officials told the advisory panel on Friday that the second dose will help increase people’s immune protection starting two to six months after the first dose.
The company submitted the results of the study to the expert group, and the results showed that two months after the first increase in COVID-19 protection from 70% to 94%, the second dose was administered. Johnson & Johnson said that the booster injection six months later resulted in a greater jump in antiviral antibodies.
Johnson & Johnson recommends that people get the second dose of vaccine two to six months after the first dose of vaccine [File: Mark Lennihan/AP Photo]But FDA scientists are questioning the company’s claims.
“Data shows that the effectiveness of this vaccine is actually not as good as the company’s introduction here,” said Dr. Peter Marks, the top FDA vaccine official. “This is a worrying finding, especially because it may be seen in minority communities and other communities.”
FDA reviewers found no new safety issues after the second dose of Johnson & Johnson, but they again warned of the small number of patients in the Johnson & Johnson study and the limited follow-up of patients.
Johnson & Johnson vaccine is highly anticipated because of its one-time formula.
But its launch earlier this year was affected by a series of issues, such as manufacturing issues and some rare but serious side effects, including blood clot disorders and a neurological response called Guillain-Barré syndrome.
In both cases, regulators believe that the benefits of injection outweigh the risks.
In addition, the “Wall Street Journal” quoted people familiar with the matter as reported that the US Food and Drug Administration on Friday postponed authorization of Moderna to provide COVID-19 vaccine to teenagers to assess whether the vaccine would increase the risk of heart inflammation.
US President Joe Biden is Promote Americans Data from the White House shows that about 66 million adults have not yet been vaccinated.
[ad_2]
Source link